NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
Clinical Trials
3 trialsNCT01801111 2018-11-02
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Hoffmann-La Roche
Phase 1/2 Completed
NCT01871805 2018-08-21
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 1/2 Completed